你妈人家下午就发消_老虎社区_美港股上老虎

云儿
2025-12-17

你妈人家下午就发消息出来了你现在才发出来真🐶

JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10<blockquote>摩根大通将 Recursion Pharmaceuticals 评级从中性上调至跑赢大盘，将 PT 从 10 美元调整至 11 美元</blockquote>

Recursion Pharmaceuticals (RXRX) has an average rating of overweight and mean price target of $7, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f

JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10<blockquote>摩根大通将 Recursion Pharmaceuticals 评级从中性上调至跑赢大盘，将 PT 从 10 美元调整至 11 美元</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":511818348110304,"tweetId":"511818348110304","gmtCreate":1765982614100,"gmtModify":1765982653362,"author":{"id":3459108227126515,"idStr":"3459108227126515","authorId":3459108227126515,"authorIdStr":"3459108227126515","name":"云儿","avatar":"https://static.tigerbbs.com/9032a2e7a964da6984df653d2f9560ed","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>你妈 人家下午就发消息出来了&nbsp; 你现在才发出来 真🐶</p></body></html>","htmlText":"<html><head></head><body><p>你妈 人家下午就发消息出来了&nbsp; 你现在才发出来 真🐶</p></body></html>","text":"你妈 人家下午就发消息出来了 你现在才发出来 真🐶","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/511818348110304","repostId":2592902419,"repostType":2,"repost":{"id":"2592902419","kind":"highlight","weMediaInfo":{"introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"media_name":"MT Newswires Live","id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"pubTimestamp":1765976995,"share":"https://www.laohu8.com/m/news/2592902419?lang=zh_CN&edition=full","pubTime":"2025-12-17 21:09","market":"nz","language":"en","title":"JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10<blockquote>摩根大通将 Recursion Pharmaceuticals 评级从中性上调至跑赢大盘，将 PT 从 10 美元调整至 11 美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902419","media":"MT Newswires Live","summary":"Recursion Pharmaceuticals (RXRX) has an average rating of overweight and mean price target of $7, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","content":"<p><html><body> <a href=\"https://laohu8.com/S/RXRX\">Recursion</a> Pharmaceuticals (RXRX) has an average rating of overweight and mean price target of $7, according to analysts polled by FactSet.</p><p><blockquote><html><body><a href=\"https://laohu8.com/S/RXRX\">递归</a>FactSet 调查的分析师表示，制药公司 (RXRX) 的平均跑赢大盘评级和平均目标价为 7 美元。</body></html></blockquote></p><p>(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)</p><p><blockquote>（MT Newswires 涵盖北美、亚洲和欧洲主要银行和研究公司的股票、大宗商品和经济研究。研究提供商可以在这里联系我们：https://www.mtnewswires.com/contact-us）</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","source":"mtnewswires_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10<blockquote>摩根大通将 Recursion Pharmaceuticals 评级从中性上调至跑赢大盘，将 PT 从 10 美元调整至 11 美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10<blockquote>摩根大通将 Recursion Pharmaceuticals 评级从中性上调至跑赢大盘，将 PT 从 10 美元调整至 11 美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-12-17 21:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body> <a href=\"https://laohu8.com/S/RXRX\">Recursion</a> Pharmaceuticals (RXRX) has an average rating of overweight and mean price target of $7, according to analysts polled by FactSet.</p><p><blockquote><html><body><a href=\"https://laohu8.com/S/RXRX\">递归</a>FactSet 调查的分析师表示，制药公司 (RXRX) 的平均跑赢大盘评级和平均目标价为 7 美元。</body></html></blockquote></p><p>(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)</p><p><blockquote>（MT Newswires 涵盖北美、亚洲和欧洲主要银行和研究公司的股票、大宗商品和经济研究。研究提供商可以在这里联系我们：https://www.mtnewswires.com/contact-us）</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RXRX":"Recursion Pharmaceuticals, Inc.","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4609":"英伟达持仓股","BK4611":"AI医疗","BK4166":"消费信贷","BK4539":"次新股"},"source_url":"https://www.mtnewswires.com/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2592902419","content_text":"Recursion Pharmaceuticals (RXRX) has an average rating of overweight and mean price target of $7, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)","news_type":1,"symbols_score_info":{"RXRX":1.95}},"isVote":1,"tweetType":1,"viewCount":1702,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":44,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}